ACHC
Acadia Healthcare Company, Inc.
$31.43
+4.14% 2026-10-20
Health CareS&P 600
ACHCSPY
1W
+4.0%
1M
+10.9%
3M
-11.7%
6M
+14.5%
YTD
+121.5%
1Y
+31.2%
Live chart
Loading live chart…
Grades vs sector
Momentum63rd pct in sectorB-
Momentum
63rd pct in sector
12-1 return: +27.9%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth9th pct in sectorD-
Growth
9th pct in sector
Revenue growth (YoY): -0.4%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value68th pct in sectorB
Value
68th pct in sector
Forward E/P: 6.2% · EBITDA/EV: 9.9%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability5th pct in sectorF
Profitability
5th pct in sector
Profit margin: -33.4% · Return on equity: -41.4%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15not ranked (outside this model's universe or screens)
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsKey stats
Market cap$2.9B
P/E (trailing)–
P/E (forward)17.0
52-week range11.43 – 35.83
Revenue growth (YoY, latest qtr)-0.4%
Dividend yield0.00%
Analyst consensusBuy (14)
Mean price target$33.79 (+7%)
Valuation and fundamentals
Valuation & fundamentals
Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score -1 (DCF counts double).
•Forward P/E vs sector17.0x vs median 17.6x
•Piotroski F-score5/9
▼Altman Z1.4 (distress)
•Net debt / EBITDA3.0x
•Analyst target+7% (14 analysts)
Discounted cash flow
Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-03-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.62 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
sector median 29.9×
–Forward P/E
cheaper
sector median 17.6× · 47th pct
17.0×cheaper
EV / EBITDA
cheaper
sector median 15.8× · 5th pct
6.8×cheaper
Price / sales
cheaper
sector median 3.1× · 17th pct
0.9×cheaper
Price / book
cheaper
sector median 3.5× · 15th pct
1.5×cheaper
FCF yield
pricier
sector median 4.1% · 3rd pct
-10.0%pricier
Forward EPS $1.85 vs trailing $-12.42. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Gross margin
–
Operating margin
17.3%
FCF margin
-8.7%
Net margin
-32.8%
Return on equity
-56.5%
Return on invested capital
10.6%
Net debt / EBITDA
3.0×
Current ratio
1.7×
Interest cover
16.5×
Cash conversion (OCF/NI)
–
Piotroski F-score 5/9 · last two fiscal years
✗ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved
Altman Z-score 1.4 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$34
+7%
Analysts
14
Buy
Range
$17–$41
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $3.3B | $-1.1B | $-439.9M |
| 2024 | $3.2B | $255.6M | $-560.7M |
| 2023 | $2.9B | $-21.7M | $38.2M |
| 2022 | $2.6B | $273.1M | $84.4M |
| 2021 | $2.3B | $190.6M | $129.7M |
| 2020 | $2.1B | $-672.1M | $433.8M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +8.3%.
Earnings
Next report: 2026-11-04 · during market · EPS est 0.46
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-07-28 | 0.35 | 0.38 | +9.7% |
| 2026-04-29 | 0.26 | 0.37 | +39.7% |
| 2026-02-25 | 0.01 | 0.07 | +593.1% |
| 2025-11-05 | 0.66 | 0.72 | +9.2% |
| 2025-08-05 | 0.71 | 0.83 | +17.4% |
| 2025-05-12 | 0.36 | 0.40 | +12.0% |
| 2025-02-27 | 0.71 | 0.64 | -10.4% |
| 2024-10-30 | 0.90 | 0.91 | +1.2% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $865.8M | -0.4% |
| 2026-03-31 | $828.8M | – |
| 2025-12-31 | $821.5M | – |
| 2025-09-30 | $851.6M | – |
| 2025-06-30 | $869.2M | – |
Analyst actions
Leerink Partners
PT $33
2026-09-23 · main
Market Perform → Market PerformPT $33
Guggenheim
PT $39
2026-07-30 · main
Buy → BuyPT $39
Barclays
PT $32
2026-07-30 · main
Equal-Weight → Equal-WeightPT $32
Guggenheim
PT $38
2026-07-20 · main
Buy → BuyPT $38
TD Cowen
PT $36
2026-07-14 · main
Buy → BuyPT $36
Keybanc
PT $40
2026-07-14 · main
Overweight → OverweightPT $40
Insider trades
None
–
None · None
SELL–
Stats refreshed 2026-10-20 18:03:21 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.